Urea cycle defects presenting in the neonatal period with hyperammonaemia are associated with high morbidity and mortality, and necessitate liver transplantation for long-term management. Gene therapy is therefore an attractive possibility, with vectors based on adeno-associated virus (rAAV) currently showing exciting promise in liver-targeted clinical trials in adults. Successful use of rAAV vectors in infants, however, is more challenging as episomal rAAV genomes will be lost from proliferating hepatocytes during liver growth, leaving stable transgene expression dependent on the subset of vector genomes that undergo genomic integration. To explore this challenge, we exploited the partially ornithine transcarbamylase (OTC)-deficient spf ash mouse model and small hairpin RNA-mediated knockdown of residual endogenous OTC enzyme activity in adult mice that had received neonatal treatment with an OTC-encoding rAAV. This leaves mice reliant on vector-encoded OTC activity that has persisted from the newborn period. Despite stable transduction in approximately 8% of hepatocytes and residual vector-encoded OTC activity of up to 33% of wild-type, well above endogenous spf ash levels (5-7%), mice were not protected from hyperammonaemia. These data show that the distribution of OTC activity within the liver is critical and that rAAV vector re-delivery after early neonatal treatment is likely to be necessary for stable control of hyperammonaemia into adulthood.
INTRODUCTION
A major challenge faced in the use of adeno-associated virus (rAAV) for liver-targeted gene therapy in the paediatric population will be maintenance of sufficient levels of therapeutic gene expression in the growing liver. This reflects the fact that the majority of rAAV genomes remain episomal with only a small proportion undergoing genomic integration. 1, 2 In tissues with low rates of cellular replication, such as adult mouse liver, persistence of episomal vector genomes is relatively stable, 3 whereas in tissues with high rates of cellular replication, such as the neonatal liver, episomal vector genomes are rapidly lost by dilution and degradation, [4] [5] [6] leaving stable long-term transgene expression dependent on vector genomes that have undergone genomic integration. 7 We are interested in developing rAAV-mediated gene therapy for infants with urea cycle disorders, in particular those presenting in the neonatal period. Affected infants have an inability to detoxify ammonia, resulting in hyperammonaemia with high morbidity and mortality. Gene therapy has great potential for therapeutic benefit in these patients by preventing hyperammonaemic episodes while awaiting liver transplantation, and possibly averting the need for transplantation altogether. In earlier studies, 8, 9 we have used the spf ash mouse model of partial ornithine transcarbamylase (OTC) deficiency to explore the therapeutic efficacy of rAAV2/8-mediated gene delivery to the mouse liver. These mice have a mild metabolic phenotype due to residual OTC enzyme activity (5-7%) with marked orotic aciduria, but no clinically significant hyperammonaemia. 10 Robust and lifelong metabolic correction were achieved in adult mice, as judged by normalisation of urinary orotic acid. 8 In contrast, correction of orotic aciduria was transient in mice treated as neonates despite modest levels of liver-wide OTC expression (B13.1% wild type) persisting into adulthood. A basal level of stably transduced hepatocytes (5-8%) remained, presumably due to vector integration. Although vector loss is likely to occur more rapidly in the mouse compared with humans, because of the higher rate of hepatocyte turnover, a similar outcome is predicted. Given that the clinically relevant feature of OTC deficiency is elevated plasma ammonia, an important unanswered question is whether the remaining stable transgene expression observed after neonatal treatment is sufficient to protect against hyperammonaemia in adulthood.
To explore this question, we exploited our previously reported small hairpin RNA (shRNA)-based strategy, which specifically knocks down endogenous OTC activity, converting spf ash mice to a severe hyperammonaemic phenotype. 9 Endogenous OTC activity was knocked down in young adult mice that had been treated with an OTC-encoding AAV2/8 vector in the early neonatal period. This experimental strategy demonstrated that the residual vector-encoded OTC activity persisting to adulthood was 1 insufficient to prevent hyperammonaemia once the background endogenous OTC activity present in spf ash mice was knocked down. These data highlight the challenge posed to liver-targeted gene therapy for urea cycle defects by liver growth, and support the view that vector re-administration is likely to be required to maintain therapeutic efficacy to adulthood after treatment in infancy. Realisation of the therapeutic potential of rAAV in the paediatric population is therefore likely to require strategies to avoid anti-capsid immune responses that will impede re-delivery, and/or strategies to enhance the stability of rAAV during liver growth.
RESULTS AND DISCUSSION
The experimental strategy used in this study involved the delivery of an AAV vector encoding an shRNA to knock down endogenous OTC enzyme activity in young adult spf ash mice that had been treated as neonates with an AAV vector encoding the murine OTC (mOTC) open reading frame. Mice were then monitored for up to 28 days for the development of neurological signs indicative of hyperammonaemia (decreased activity, tremor and ataxia, progressing to coma; Figure 1 ). Successful knockdown of endogenous OTC activity renders mice dependent on residual OTC activity, expressed from vector genomes persisting in the liver from the time of neonatal treatment. The development or prevention of hyperammonaemia, therefore, provides a direct read-out of the therapeutic sufficiency of vector-encoded OTC activity persisting to adulthood.
In an initial experiment ( Figure 2 ), newborn (1-2 days) spf ash mice were injected via the intraperitoneal (i.p.) route with rAAV2/ 8-LSP1.mOTC, in conventional single-stranded configuration, and upon reaching young adulthood (8-10 weeks) were injected i.p. with rAAV2/8-H1.shRNA (knockdown vector). Positive and negative control groups were included using PBS instead of vector for the neonatal and adult injections, respectively. All mice receiving PBS instead of the knockdown vector survived without developing hyperammonaemia (111 ± 17 mmol l À 1 , n ¼ 6), whereas all mice receiving PBS in the neonatal period developed hyperammonaemia (1906 ± 348 mmol l À 1 , n ¼ 3) in adulthood after treatment with the knockdown vector. In the group receiving rAAV2/8-LSP1.mOTC in the neonatal period and rAAV2/8-H1.shRNA in young adulthood (n ¼ 12), variable outcomes were observed. Half developed severe hyperammonaemia (1652 ± 351 mmol l À 1 , n ¼ 6) after treatment with the knockdown vector despite residual OTC activities ranging between 11 and 32% of wild-type levels (11.5±2%). The other half remained healthy with ammonia levels (104 ± 33 mmol l À 1 , n ¼ 6) equivalent to control mice that had received PBS instead of knockdown vector. Superficially, these results were consistent with the possibility that residual levels of vector-encoded OTC persisting to adulthood following neonatal treatment were sufficient, at least in a proportion of mice, to prevent hyperammonaemia. Vector genome copy number analysis, however, revealed that mice remaining healthy had undetectable levels of the knockdown vector in their livers, whereas mice developing hyperammonaemia had high vector genome (vg) copy numbers (176±88 vg per diploid cell, n ¼ 6). We hypothesised that this variability might be explained by either a technical problem with vector delivery and/or induction of an anti-capsid immune response preventing vector re-delivery in a proportion of adult mice following neonatal vector exposure. We have previously shown that while vector re-administration following neonatal injection is possible, the level of transduction is frequently reduced. 5 To limit potential anti-capsid immune responses, we repeated the experiment using different capsid serotypes for delivery in the neonatal period and early adulthood. We also independently explored whether using a self-complementary (sc) vector genome configuration for delivery of OTC in the newborn period might be more effective (Figure 3) . Regardless of the vector genome configuration of the therapeutic vector, all mice that received the knockdown vector as adults developed hyperammonaemia. All mice that received the single-stranded vector developed neurological signs within 6-11 days with elevated plasma ammonia (2072±611 mmol l À 1 , n ¼ 6), despite OTC activities in the range 6.0-12.2% wt, and all mice that received the sc vector developed neurological signs within 9-14 days with elevated plasma ammonia (2543 ± 1093 mmol l À 1 , n ¼ 7) despite activities in the range 5.3-13.3% wt.
Based on a recent publication indicating that a greater level of stable transduction could be achieved in neonatal mice using the rh10 capsid, 11 a third set of experiments was carried out where the Figure 1 . Experimental protocol for administration of rAAV-encoding murine OTC (mOTC) and subsequent knockdown with rAAV-encoding endogenous OTC-specific shRNA. All injections were via the intra-peritoneal route into spf ash male mice. Vectors were pseudo-serotyped with either the Type 8 capsid (rAAV2/8) or with the rh10 capsid (rAAV2/rh10). Following administration of the knockdown vector, mice were monitored for signs of severe hyperammonaemia, upon which they were killed and blood and liver taken for analysis. Remaining mice were killed 4 weeks after injection of knockdown vector. therapeutic vector was pseudo-serotyped with the rh10 capsid and the knockdown vector was pseudo-serotyped in the AAV8 capsid. However, despite achieving increased OTC activity when compared with the previous two experiments, ranging from 11.9 to 33.8% wt, again all mice developed neurological signs with elevated plasma ammonia (1015 ± 332 mmol l À 1 , n ¼ 5) within 6-9 days of treatment with the knockdown vector.
Given that protection was not achieved despite exogenous OTC activity reaching levels considerably higher than endogenous levels in spf ash mice (5-7% of wt OTC activity), which are not hyperammonaemic under routine conditions, we then looked at the distribution of exogenous OTC activity in individual cells across the liver (Figure 4 ). Although exogenous OTC activity was at a supra-physiological level within transduced hepatocytes, only a small proportion of hepatocytes were stably transduced, and these were distributed throughout both peri-central and periportal regions of the hepatic lobule. The proportion of hepatocytes transduced in the mouse exhibiting the highest levels of liver-wide OTC activity (34% wild-type) was approximately 8%. The fact that this level of transduction was insufficient to control hyperammonaemia supports a number of conclusions. First, the threshold for control of hyperammonaemia in the spf ash knockdown model described requires stable long-term transgene expression in excess of 8% of hepatocytes, a level that cannot currently be achieved following AAV-mediated gene transfer in the newborn period. Second, the absolute number and distribution of transduced hepatocytes are more therapeutically relevant than measures of liver-wide OTC enzymatic activity, and finally endogenous OTC activity, which shows metabolic zonation across the hepatic lobule, 12 is more effective in supporting ureagenesis than vector-encoded OTC activity.
Based on these findings and our previously published data on the kinetics of AAV episome loss in the growing mouse liver, 5 vector re-administration appears likely to be required for longterm control of hyperammonaemia in severely OTC-deficient infants. A possible caveat, however, in extrapolating to humans is the significantly higher protein intake of mice, 13 which could be associated with a relatively higher threshold for phenotype correction. Also, in humans, any benefit conferred by gene therapy has the potential to be supported by ongoing medical therapy, including a low-protein diet and the use of alternate pathway therapy.
Predicting the time course of AAV episome loss in the growing human liver is difficult. In mice treated in the newborn period, almost complete loss of episomal AAV occurs within 2 weeks, during which the liver has undergone 2-3 doublings in mass. Thereafter, therapeutic efficacy is dependent on the subset of hepatocytes, which remain stably transduced, presumably through vector integration. 7 The equivalent time course for the newborn human liver to undergo 2 and 3 doublings is 2 and 9 years, respectively.
14 Interpreted conservatively, and assuming efficient initial delivery to the newborn human liver, this implies that AAV-mediated gene therapy may prove to be an effective bridge to transplant option in the first 1-2 years of life, but longer term therapeutic efficacy is unlikely in the absence of vector redelivery. The primary barrier to re-delivery is anti-capsid humoral immunity induced by initial treatment, but this may yet be overcome by use of an alternate capsid serotype for re-delivery selected from the growing repertoire available. 15 We have recently established a precedent for this possibility by successfully rescuing neonatal lethality in argininosuccinate synthetase-deficient mice with survival to adulthood achieved through vector re-delivery in an alternate capsid. 16 Alternatively, further development of strategies to increase AAV vector genome stability in replicating cells may yet allow durable life-long therapeutic control of OTC deficiency and other urea cycle defects after a single treatment in the newborn period.
MATERIALS AND METHODS

Cell culture
Human embryonic kidney 293 cells 17 were maintained in Dulbecco's modified Eagle medium (Gibco, Invitrogen, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (JRH Biosciences, Lenexa, KS, USA) and 1% (w/v) L-glutamine (Gibco, Invitrogen), and maintained at 37 1C in a humidified 5% CO 2 -air atmosphere.
Virus production
Recombinant AAV vectors were produced in human embryonic kidney 293 cells packaging pLSP1.mOTC 8 or pLSP1.eGFP-H1.OTCshRNA, 9 and pseudoserotyped with either the AAV8 or AAVrh10 capsid 18 (courtesy of James M Wilson, University of Pennsylvania) as previously described. 5 Vector genomes were titred by real-time quantitative PCR using a primer/probe set specific for the woodchuck post-transcriptional regulatory element 
Plasma ammonia analysis
Blood was collected by cardiac puncture, centrifuged at 7500 g for 5 min at 4 1C, and the plasma was snap-frozen in liquid nitrogen and stored at À 80 1C until required. Ammonia was measured using the Ammonia Assay Kit (Sigma-Aldrich, St Louis, MO, USA).
OTC enzyme activity
Liver pieces were snap-frozen in liquid nitrogen and analysed for OTC enzyme activity 20 or vector copy number (see below). The distribution of OTC activity across the hepatic lobule was determined in liver pieces fixed with 4% paraformaldehyde in phosphate-buffered saline as previously described. 20 Analysis of vector copy number Pieces of liver were snap-frozen in liquid nitrogen and stored at À 80 1C. DNA was extracted using standard phenol/chloroform and ethanol precipitation methods. 21 Vector copies per diploid cell of the knockdown vector were determined in 200-400 ng of template DNA by quantitative PCR using primers that targeted the enhanced green fluorescent protein cDNA: 5 0 -TCAAGATCCGCCACAACATC-3 0 (sense) and 5 0 -TTCTCGTTGGGGTCT TTGCT-3 0 (antisense). The samples were normalised against glyceraldehyde 3-phosphate dehydrogenase using the following primers: 
Determining the percentage of cells transduced
Transgene-expressing cells were counted across four liver sections and the total number of cells in an equivalent area was calculated by counting 4 0 -6-diamidino-2-phenylindole-stained nuclei and used to calculate the percentage of gene-modified cells.
